Next |
home / stock / cyth / cyth message board
Subject | By | Source | When |
---|---|---|---|
The now | Pedro2004 | investorshub | 05/01/2023 1:32:07 PM |
$CYTH Price trading up | tradrdad45 | investorshub | 04/30/2023 12:40:36 AM |
$CYTH MomentumIts gaining | Covid19freak | investorshub | 04/27/2023 7:53:22 AM |
$CYTH MomentumIts trading | pay in cash | investorshub | 04/26/2023 6:17:37 PM |
is it bear time? Or do we go bull? | Esa | investorshub | 04/20/2023 10:15:48 PM |
MomentumIts gaining | stockdawg44 | investorshub | 04/19/2023 3:35:46 AM |
$CYTH Time for this to show some returns | CYDYWinning | investorshub | 04/18/2023 8:16:17 PM |
great news | Esa | investorshub | 04/18/2023 6:49:35 PM |
where is the squeeze? | Lazarus | investorshub | 04/11/2023 7:19:34 PM |
$CYTH where is the squeeze? | Pedro2004 | investorshub | 04/10/2023 3:18:13 PM |
$CYTH we got news | ClayTrader | investorshub | 04/08/2023 4:42:29 AM |
Good read | thee trader | investorshub | 04/06/2023 1:52:16 PM |
$CYTH The now | tradrdad45 | investorshub | 04/04/2023 4:57:46 AM |
Price has been cut in half since you | Lazarus | investorshub | 03/29/2023 7:21:09 PM |
($CYTH) $1.90 ..MC $17 mil -has Orphan drug | Covid19freak | investorshub | 01/17/2023 8:02:43 PM |
...but, but, but https://www.otcmarkets.com/filing/html?id=16164183&guid=FC | Lazarus | investorshub | 10/31/2022 9:41:57 PM |
Insiders buying and phase 3 data coming out | Esa | investorshub | 02/08/2022 1:18:27 PM |
Picked some up today. Looks quite promising at | scotsand | investorshub | 01/06/2022 5:18:35 PM |
Trappsol Cyclo | XenaLives | investorshub | 10/08/2021 3:46:21 AM |
Yup I purchased CYTHW as well. This looks | CYDYWinning | investorshub | 04/28/2021 7:14:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Cyclo Therapeutics Inc. Company Name:
CYTH Stock Symbol:
NASDAQ Market:
Ongoing progress toward last patient enrolled in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025...
Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025 Aligned development strategy for Trappsol ...